Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Multiple Myeloma
100%
Zoledronic Acid
100%
Bisphosphonates
100%
Clinical Practice Guidelines
100%
American Society of Clinical Oncology
100%
Clinical Oncology
100%
Lytic Bone Disease
66%
Clodronate
50%
Cost-benefit
16%
United States
16%
Skeletal-related Events
16%
Myeloma
16%
Skeletal Complications
16%
Placebo
16%
Treatment Initiation
16%
Expert Consensus
16%
Survival Benefit
16%
Randomized Controlled Trial
16%
Public Policy Implication
16%
Treatment Duration
16%
Lytic Bone Lesion
16%
Published Data
16%
Committee Member
16%
Multiple Myeloma Patients
16%
Board of Directors
16%
Bone Involvement
16%
Pertinent Information
16%
Conventional Therapy
16%
When to Start
16%
Vertebral Fracture
16%
Drug Costs
16%
Multidisciplinary Panel
16%
Therapy Initiation
16%
External Review
16%
Research Committee
16%
Expert Reviewer
16%
Grading of Recommendations
16%
High-cost Drugs
16%
Health Services Research
16%
Specific Delivery
16%
Nursing and Health Professions
Practice Guideline
100%
Bisphosphonic Acid Derivative
100%
Pamidronic Acid
100%
Zoledronic Acid
100%
Multiple Myeloma
100%
Bone Disease
66%
Infusion
33%
Placebo
16%
Treatment Duration
16%
Myeloma
16%
Cost Benefit Analysis
16%
Drug Cost
16%
Health Services Research
16%
Drug Delivery System
16%
Diseases
16%
Spine Fracture
16%
Pharmacology, Toxicology and Pharmaceutical Science
Zoledronic Acid
100%
Multiple Myeloma
100%
Bisphosphonic Acid Derivative
100%
Pamidronic Acid
100%
Bone Disease
66%
Clodronic Acid
50%
Myeloma
16%
Placebo
16%
Spine Fracture
16%
Bone Lesion
16%
Randomized Controlled Trial
16%
Diseases
16%